Neuropsychomotor development characteristics of the infants who born from women who abused drugs during pregnancy
Introduction: The use of street drugs during pregnancy, due to their deleterious effects on the health of the infant, may have clinical implications for neuropsychomotor development.
Objective: The aim of this study was to analyse the characteristics of the neuropsychomotor development of infants born from women who used street drugs during pregnancy.
Methods: A cross-sectional retrospective study was carried out. A total of 51 medical records of infants weighing less than 1.500 grams, who were born in the Hospital de Clínicas da Universidade Federal de Uberlândia (HC/UFU), Minas Gerais, Brazil, from January 2014 to December 2015 were analysed. Using the Development Screening test Denver II at 6 or 9 months of corrected age performed the neuropsychomotor development evaluation. Statistical analysis included quantitative variables that were described by means of average, medians and standard deviation. Groups were compared by the t test or Mann-Whitney test. The associations of the qualitative variables were evaluated by means of the likelihood ratio test.
Results: Of the 51 records analysed, 39.2% belong to the group of children of mothers who used street drugs and 60.8% belong to the group of children of nonuser mothers. The neuropsychomotor development was predominantly abnormal and with a significant difference in the general performance classification (p<0.001) and, specifically, in the coarse motor area (p = 0.003) in the group of infants born to mothers who used street drugs.
Conclusion: Infants of mothers who used street drugs had a greater delay in neuropsychomotor development.
Albrecht J, Lindsay B, Terplan M. Effect of waiting time on substance abuse treatment completion in pregnant women. J Subst Abuse Treat. 2011;41(1):71-7. DOI: http:/dx.doi.org/10.1016/j.jsat.2011.01.015
Gabrhelík R, Nechanská B, Mravcik V, Skurtveit S, Lund IO, Handal M. A unique opportunity to study short and long term consequences in children prenatally exposed to lIlicit drugs and opioid maintenance treatment using czech and scandinavian registers. Cent Eur J Public Health. 2016;24(3):248-51. DOI: http:/dx.doi.org/10.21101/cejph.a4474
Department of Health and Human Services. Results from the 2010 national survey on drug use and health: summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011.
Rocha PC, Alves MTSSB, Chagas DC, Silva AAM, Batista RFL, Silva RA. Prevalência e fatores associados ao uso de drogas ilícitas em gestantes da corte BRISA. Cad Saúde Pública. 2016;32(1):1-13. DOI: http://dx.doi.org/10.1590/0102-311X00192714
Yamaguchi ET, Cardoso MMSC, Torres MLA, Andrade AG. Drogas de abuso e gravidez. Rev Psiquiatr Clín. 2008;35(Suppl 1):44-7. DOI: http://dx.doi.org/10.1590/S0101-60832008000700010
Nicolau CM. Filhos de mães drogaditas. PROFISIO Programa de Atualização em Fisioterapia Pediátrica e Neonatal: Cardiorrespiratória e Terapia Intensiva.V.4. Porto Alegre: Artmed Panamericana, 2016; p.9:26.
Bell SG. Drug screening in neonates. Neonatal Netw. 2016;35(5):321-6. DOI: http://dx.doi.org/10.1891/0730-0818.104.22.1681
Frankenburg WK, Dodds J, Archer P, Shapiro M, Bresnick B. The Denver II: a major revision and restandartization of the Denver developmental screening test. Pediatrics. 1992;89(1):91-7.
Souza SC, Leone C, Takano OA, Moratelli HB. Desenvolvimento de pré-escolares na educação infantil em Cuiabá, Mato Grosso, Brasil. Cad Saúde Pública. 2008;24(8):1917-26. DOI: http://dx.doi.org/10.1590/S0102-311X2008000800020
Rodrigues OMPR, Bolsoni-Silva AT. Effects of the Prematurity on the Development of Lactentes. Rev Bras Crescimento Desenvolv Hum. 2011;21(1):111-21. DOI: http://dx.doi.org/10.7322/jhgd.20000
Miller-Loncar C, Lester BM, Seifer R, Lagasse LL, Bauer CR, Shankaran S, et al. Predictors of motor development in children prenatally exposed to cocaine. Neurotoxicol Teratol. 2005;27(2):213-20. DOI: http://dx.doi.org/10.1016/j.ntt.2004.10.007
Belcher HM, Shapiro BK, Leppert M, Butz AM, Sellers S, Arch E, et al. Sequential neuromotor examination in children with intrauterine cocaine/polydrug exposure. Dev Med Child Neurol. 1999;41(4):240-6. DOI: http://dx.doi.org/10.1111/j.1469-8749.1999.tb00591.x
Singer LT, Moore DG, Min MO, Goodwin J, Turner JJ, Fulton S, et al. Motor delays in MDMA ( ecstasy) exposed infants persist to 2 years. Neurotoxicol Teratol. 2016;54:22-8. DOI: http://dx.doi.org/10.1016/j.ntt.2016.01.003
Lucca J, Baldisserotto M. Cerebral ultrasound findings in infants exposed to crack cocaine during gestation. Pediatr Radiol. 2013;43(2):212-8. DOI: http://dx.doi.org/10.1007/s00247-012-2528-6
Dixon SD, Bejar R. Echoencephalographic findings in neonates associated with maternal cocaine and methamphetamineuse: incidence and clinical correlates. J Pediatr. 1989;115(5 Pt 1):770-8.
Konijnenberg C. Methodological issues in assessing the impact of prenatal drug exposure. Subst Abuse. 2015;9(Suppl.2):39-44. DOI: http://dx.doi.org/10.4137/SART.S23544
Sampaio TF, Nogueira KPA, Pontes TB, Toledo AM. Comportamento motor de lactentes prematuros de baixo peso e muito baixo peso ao nascer. Fisioter Pesq. 2015;22(3):253-60. DOI: http://dx.doi.org/10.590/1809-2950/13533022032015
Kassada DS, Marcon SS, Pagliarini MA, Rossi RM. Prevalência do uso de drogas de abuso por gestantes. Acta Paul Enferm. 2013;26(5):467-71. DOI: http://dx.doi.org/10.1590/S0103-21002013000500010
Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? J Pharmacol Exp Ther. 1998;285(3):931-45.
Bauer CR, Shankaran S, Bada HS, Lester B, Wright LL, Krause-Steinrauf H, et al. The maternal lifestyle study: drug exposure during pregnancy and short-term maternal outcomes. Am J Obstet Gynecol. 2002;186(3):487-95. DOI: https://doi.org/10.1067/mob.2002.121073
Momimo W, Sanseverino MTV, Schüler-Faccin L. A exposição pré-natal ao álcool como fator de risco para comportamentos disfuncionais: o papel do pediatra. J Pediatr. 2008;84(Suppl 4):76-9. DOI: http://dx.doi.org/10.1590/S0021-7 5572008000500011
Ornoy A, Ergaz Z. Alcohol abuse in pregnant women: effects on the fetus and newborn, mode of action and maternal treatment. Int J Environ Res Public Health. 2010;7(2):364-79. DOI: http://dx.doi.org/10.3390/ijerph7020364
Marin GH, Delgado L, Sager G, Visentín S, Azzaro S, Tozzi M. Consequences of smoking during pregnancy for mother and child. Saúde Mater Infant. 2003;3(2):159-64. DOI: http://dx.doi.org/10.1590/S1519-38292003000200005
Lendoiro E, González-Colmenero E, Concheiro-Guisán A, Castro A, Cruz A, López-Rivadulla M, et al. Maternal hair analysis for the detection of lllicit drugs, medicines, and alcohol exposure during pregnancy. Ther Drug Monit. 2013;35(3):296-304. DOI: http://dx.doi.org/10.1097/FTD.0b013e318288453f
Oliveira TA, Bersusa AAS, Santos TF, Aquino MMAA, Mariani Neto C. Perinatal outcomes in pregnant women users of lllegal drugs. Rev Bras Ginecol Obstet. 2016;38(4):183-8. DOI: http://dx.doi.org/10.1055/s-0036-1580710
White SM, Lambe CJ. The pathophysiology of cocaine abuse. J Clin Forensic Med. 2003;10(1):27-39. DOI: http://dx.doi.org/10.1016/S1353-1131(03)00003-8
Vettore MV, Dias M, Domingues RMSM, Vettore MV, Leal MC. Cuidados pré-natais e avaliação de manejo da hipertensão arterial em gestantes do SUS no município do Rio de Janeiro, Brasil. Cad Saude Publica. 2011;27(5):1021-34. DOI: http://dx.doi.org/10.1590/S0102-311X2011000500019
Carvalho MAB, Melo VH, Zimmermmann JB. Resultados perinatais de gestantes com síndrome hipertensiva da Santa Casa de Misericórdia de Barbacena, Minas Gerais: estudo controlado. Rev Med Minas Gerais. 2008;18(4):260-6.
Melo VH, Botelho AOM, Maia MMM, Júnior MDC, Pinto JA. Uso de drogas ilícitas por gestantes infectadas pelo HIV. Rev Bras Ginecol Obstet. 2014;36(12):555-61. DOI: http://dx.doi.org/10.1590/So100-720320140005155
Castellanos GRR, Rodríguez SLR. Neonatal sepsis and neurodevelopment in very low birth weight infants in Matanzas, Cuba 2006- 2010: a prospective cohort study. Medwave. 2016;16(3):e6422. DOI: http://dx.doi.org/10.5867/medwave.2016.03.6422
Ferreira RC, Mello RR, Silva KS. Neonatal sepsis as a risk factor for neurodevelopmental changes in preterm infants with very low birth weight. J Pediatr. 2014;90(3):293-9. DOI: http://dx.doi.org/10.1016/j.jped.2013.09.006
Schempf AH. Ilicit drug use and neonatal outcomes: a critical review. Obstet Gynecol Surv. 2007;62(11):749-57. DOI: http://dx.doi.org/10.1097/01.ogx.0000286562.31774.76
CODE OF CONDUCT FOR JOURNAL PUBLISHERS
Publishers who are Committee on Publication Ethics members and who support COPE membership for journal editors should:
- Follow this code, and encourage the editors they work with to follow the COPE Code of Conduct for Journal Edi- tors (http://publicationethics.org/files/u2/New_Code.pdf)
- Ensure the editors and journals they work with are aware of what their membership of COPE provides and en- tails
- Provide reasonable practical support to editors so that they can follow the COPE Code of Conduct for Journal Editors (http://publicationethics.org/files/u2/New_Code.pdf_)
- Define the relationship between publisher, editor and other parties in a contract
- Respect privacy (for example, for research participants, for authors, for peer reviewers)
- Protect intellectual property and copyright
- Foster editorial independence
Publishers should work with journal editors to:
- Set journal policies appropriately and aim to meet those policies, particularly with respect to:
– Editorial independence
– Research ethics, including confidentiality, consent, and the special requirements for human and animal research
– Transparency and integrity (for example, conflicts of interest, research funding, reporting standards
– Peer review and the role of the editorial team beyond that of the journal editor
– Appeals and complaints
- Communicate journal policies (for example, to authors, readers, peer reviewers)
- Review journal policies periodically, particularly with respect to new recommendations from the COPE
- Code of Conduct for Editors and the COPE Best Practice Guidelines
- Maintain the integrity of the academic record
- Assist the parties (for example, institutions, grant funders, governing bodies) responsible for the investigation of suspected research and publication misconduct and, where possible, facilitate in the resolution of these cases
- Publish corrections, clarifications, and retractions
- Publish content on a timely basis